Doximity (NASDAQ:DOCS – Free Report) had its price objective increased by Wells Fargo & Company from $25.00 to $27.00 in a research report report published on Friday, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.
Several other analysts have also recently weighed in on DOCS. Morgan Stanley lifted their price target on shares of Doximity from $21.00 to $25.00 and gave the company an underweight rating in a report on Friday, November 10th. Piper Sandler lifted their price target on Doximity from $21.00 to $23.00 and gave the stock a neutral rating in a research report on Friday, November 10th. Bank of America boosted their target price on Doximity from $29.00 to $32.00 and gave the stock a neutral rating in a research report on Tuesday, January 23rd. Finally, Barclays started coverage on shares of Doximity in a research report on Wednesday, January 3rd. They set an equal weight rating and a $31.00 price target for the company. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus target price of $28.10.
Doximity Stock Performance
Insider Buying and Selling
In other news, Director Kira Scherer Wampler sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $28.27, for a total value of $141,350.00. Following the completion of the sale, the director now directly owns 10,258 shares of the company’s stock, valued at approximately $289,993.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 39.40% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Doximity
Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in shares of Doximity by 60.6% during the first quarter. Bank of New York Mellon Corp now owns 172,855 shares of the company’s stock valued at $9,004,000 after purchasing an additional 65,196 shares during the last quarter. US Bancorp DE boosted its position in Doximity by 325.4% during the first quarter. US Bancorp DE now owns 2,646 shares of the company’s stock valued at $138,000 after purchasing an additional 2,024 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of Doximity by 417.4% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 21,099 shares of the company’s stock worth $1,099,000 after buying an additional 17,021 shares during the last quarter. Natixis Advisors L.P. acquired a new stake in shares of Doximity in the first quarter worth about $983,000. Finally, BlackRock Inc. increased its stake in shares of Doximity by 53.6% in the first quarter. BlackRock Inc. now owns 2,052,183 shares of the company’s stock worth $106,898,000 after purchasing an additional 716,547 shares during the period. Hedge funds and other institutional investors own 54.65% of the company’s stock.
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
- Five stocks we like better than Doximity
- How to Invest in Casino Stocks
- 3 attractive stocks that insiders are buying
- When to Sell a Stock for Profit or Loss
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Use the MarketBeat Excel Dividend Calculator
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.